Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension

International Journal of Cardiology

Volumn 74, Issue 1, 2000, Pages 77-84

  De Rosa, Maria Leonarda ^a   Maddaluno, Gennaro ^a   Lionetti, Francesco ^a   Di Palma, Umberto ^a   Albanese, Luigi ^a   Cardace, Piercarmine ^a   Baiano, Antonio ^a   Vigorito, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Enalapril; Hypertension; Isradipine; Left ventricular hypertrophy

Indexed keywords

ENALAPRIL; ISRADIPINE; POTASSIUM ION; SODIUM ION;

ADULT; ARTICLE; B SCAN; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENALAPRIL; GLOMERULAR FILTRATION RATE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ISRADIPINE; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0034641115     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00249-7     Document Type: Article

References (39)

1. Frohlich E.D. Cardiac hypertrophy in hypertension. N Engl J Med. 317:1987;813-823.
2. Hansson L. Reversal of cardiac and vascular hypertrophy by antihypertensive therapy. Am Heart J. 121:1991;995-998.
3. Strauer B.E. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol. 44:1979;999-1006.
4. Tarazi R.C., Fouad F.M. Reversal of cardiac hypertrophy by medical treatment. Annu Rev Med. 1:1985;407-412.
5. Klaus D. Regression of left ventricular hypertrophy in chronic hypertension: experimental animal models and clinical studies. Z Kardiol. 74:(suppl 7):1985;153-169.
6. Tarazi R.C., Sen S., Fouad F.M., Wicker P. Regression of myocardial hypertrophy: condition and sequelae of reversal in hypertensive heart disease. Perspect Cardiovasc Res. 7:1983;637-652.
7. Wollam G.L., Hall W.D., Porter V.D., et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med. 75:(3A):1983;100-110.
8. Drayer J.I.M., Gardin J.M., Weber M.A., Aronow W.S. Cardiac muscle mass during vasodilation therapy of hypertension. Clin Pharmacol Ther. 33:1983;727-732.
9. Relcheck N., Franklin B.B., Chandler T., Muhammad A., et al. Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J. 3:(suppl A):1982;165-169.
10. Muiesan G., Agabiti-Rosei E., Romanelli G., Muiesan M., et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. Am J Med Cardiol. 57:1986;44-46.
11. Strauer B.E. Functional dynamics of the left ventricle in hypertensive hypertrophy and failure. Hypertension. 6:(suppl 3):1984;412.
12. Klaus D., Lederle R.M., Saul F. Regression of hypertensive left ventricular hypertrophy after one year treatment with combination of verapamil, hydrochlorothiazide and triamterene. Herz. 21:1989;222-228.
13. Mehlsen J., Gleerup G., Haedersdal C., Winther K. Beneficial effect of isradipine on the development of the left ventricular hypertrophy in mild hypertension. Am J Hypertens. 6:1993;9597-9634.
14. Trimarco B., Wikstrand J. Regression of cardiovascular structural changes by antihypertensive treatment. Hypertension. 6:(suppl 111):1984;150-157.
15. Mujais S.K., Tarazi R.C., Fouad F.M., Bravo E.L. Reversal of left ventricular hypertrophy with captopril. Clin Cardiol. 6:1983;592-602.
16. Sahn D.J., De Maria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echography: results of a survey of echocardiographic measurements. Circulation. 58:1978;1072.
17. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation. 55:1977;163.
18. Stefadouros M.A., Dougherty M.J., Grossman W., Craige E. Determinations of systemic vascular resistance by non invasive technique. Circulation. 47:1973;101.
19. Reichek N., Wilson J., Sutton M.J., Plappert T.A., et al. Non invasive determination of left ventricular endsystolic stress: validation of the method and initial application. Circulation. 65:1982;99.
20. Gates G.F. Glomerular filtration rate: estimation from fractional renal accumulation of Tc99m DTPA (stannous). Am J Roentgen. 138:1982;565-570.
21. Gates G.F. Split renal function testing using Tc99m DTPA. A rapid technique for determining differential glomerular filtration. Clin Nucl Med. 8:1983;400407.
22. Armitage P. Statistical methods in medical research. 1971;Blackwell, New York.
23. Todd P.A., Hell R.C. Enalapril a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 31:1986;198-248.
24. Reid J.L. Dose plasma concentration effect relationship of felodipine in essential hypertension: a review. J Cardiovasc Pharmacol. 15:(suppl 4):1990;S50-S56.
25. Smith S.A., Mace P.J.E., Littler W.A. Felodipine, blood pressure and cardiovascular reflexes in hypertensive humans. Hypertension. 8:1986;1172-1178.
26. McMahon S., Cutler J.A., Furberg D., et al. The effects of drug treatment for hypertension on mortality and morbidity from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 29:(suppl 1):1986;99-118.
27. Devereux R.B. Importance of left ventricular mass as a predictor of cardiovascular morbidity in hypertension. Am J Hypertens. 2:1989;650-654.
28. Krussell L.R., Jespersen L.T., Schmitz A., Thomsen K., et al. Repetitive natriuresis and blood pressure. Long term calcium entry blockade with isradipine. Hypertension. 10:1987;577-581.
29. Lederballe Pederson O., Krussel L.R., Sihm I., Jespersen L.T., et al. Longterm effects of isradipine on blood pressure and renal function. Am J Med. 86:(suppl 4A):1989;15-18.
30. Persson B., Andersson O.K., Wysocki M., Hedner T., et al. Renal and hemodynamic effects of isradipine in essential hypertension. Am J Med. 86:(suppl 4A):1989;60-64.
31. Rupoli L., Fruscio M., Gradnik R., Chianca R., et al. Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients. Am J Med. 86:(suppl 4A):1989;65-66.
32. Urmer B.K., Hussler M., Ress K.M., Müller G., et al. Renal effects of the new calcium channel blocking drug isradipine. Eur J Clin Pharmacol. 39:1990;333-335.
33. Liebson P.R. Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens. 3:1990;512-517.
34. Vogt M., Motz W.H., Schwartzkopf B., Strauer B.E. Pathophysiology and clinical aspects of hypertensive hypertrophy. Eur Heart J. 14:(suppl D):1993;27.
35. Reicheck N., Franklin B., Chandler T., Muhammad A., et al. Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J. 3:(suppl A):1982;165-169.
36. Weber J. Left ventricular hypertrophy: its prime importance as controllable risk factor. Am Heart J. 116:1988;272-275.
37. Devereux R.B., Pickering T.G., Harshfield G.A., et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regulatory recurring stress. Circulation. 68:1983;470-476.
38. Drayer J.I.M., Weber M.A., de Young J.L. Blood pressure as a determinant of cardiac left ventricular mass. Arch Intern Med. 143:1983;90-92.
39. Motz W., Strauer B.E. Left ventricular function and collagen content after regression of hypertensive hypertrophy. Hypertension. 13:1989;43-50.